New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.

ABSTRACT:

Background

Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer (aUC) progressing after platinum-based chemotherapy. Nevertheless, existing algorithms may not be sufficient following the introduction of immunotherapy. Our aim was to develop an improved prognostic model in patients receiving second-line atezolizumab for aUC.

Methods

Patients with aUC progressing after cisplatin/carboplatin-based chemotherapy and enrolled in the prospective, single-arm, phase IIIb SAUL study were included in this analysis. Patients were treated with 3-weekly atezolizumab 1200 mg intravenously. The development a

SUBMITTER: Bamias A 

PROVIDER: S-EPMC9835946 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature